|
|
Article: InterMune Provides Update on Its Two Phase III Pulmonology Programs.
- Article from:
- PR Newswire
- Article date:
- October 17, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Phase III INSPIRE Trial on Track to Conclude Around the End of 2007 -
- Design of Phase III Pirfenidone Program Finalized -
- Company to Host Conference Call Tomorrow Morning at 8:30 A.M. ET -
BRISBANE, Calif., October 17 /PRNewswire-FirstCall/ -- InterMune, Inc. today provided an update on its two Phase III programs evaluating two separate compounds for the treatment of idiopathic pulmonary fibrosis (IPF). The update included the status of enrollment of the Phase III INSPIRE trial for Actimmune(R) (interferon gamma-1b) and details regarding the finalized protocol design of the Phase III pirfenidone program.
Strong INSPIRE Trial ...